PT Medikaloka Hermina Tbk dan entitas anaknya/and its subsidiaries

(1)

(tidak d iau d it)/

In te rim c o n s o lid a te d fin a n c ia l s ta te m e n ts as o f June 30, 2021

a n d f o r th e s ix -m o n th p e rio d then ended (u n a u d ite d )

(2)

(TIDAK DIAUDIT)

Daftar Isi Table of Contents

Halaman/Page

Surat Pernyataan Direksi Board of Directors’ Statement

Laporan Posisi Keuangan

Interim konsolidasian . 1 - 3

Interim Consolidated Statement

... of Financial Position

Laporan Laba Rugi dan Penghasilan Interim Consolidated Statement of Profit or Loss

Komprehensif Lain Interim konsolidasian... 4 - 5 ... and Other Comprehensive Income

Laporan Perubahan Ekuitas Interim konsolidasian....

Laporan Arus Kas Interim konsolidasian.

6 7 - 8

Interim Consolidated Statement

... of Changes in Equity

Catatan Atas Laporan Keuangan

Interim konsolidasian... 9 - 122

. Interim Consolidated Statement of Cash Flows

Notes to the Interim Consolidated

... Financial Statements

(3)

LAPORAN KEUANGAN INTERIM KONSOLIDASIAN TANGGAL 30 JUNI 2021

DAN UNTUK PERIODE ENAM BULAN YANG BERAKHIR PADA TANGGAL TERSEBUT (Tidak Diaudit)

PT MEDIKALOKA HERMINA TBK (“PERUSAHAAN”) DAN ENTITAS ANAKNYA

INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 AND FOR THE SIX-MONTH PERIOD THEN ENDED (Unaudited) PT MEDIKALOKA HERMINA TBK ("THE COMPANY")

AND ITS SUBSIDIARIES

Kami yang bertanda tangan di bawah ini: We, the undersigned:

Nama

Alamat kantor Alamat domisili Jabatan

Hasmoro

Jl. Selangit, Blok B. 10, Kav. 4, Kemayoran, Jakarta Pusat

Tebet Barat I No. A-3 RT 009/002, Tebet, Jakarta Selatan

Direktur Utama/Pres/cfenf Director

Name Office address Residential address Title Nama Alamat kantor Alamat domisili Jabatan Aristo S. Setiawidjaja

Jl. Selangit, Blok B. 10, Kav. 4, Kemayoran, Jakarta Pusat

Jl. Lautze Dalam No. 7B RT 001/006, Sawah Besar Jakarta Pusat

Direktur/Director Name Office address Residential address Title Menyatakan bahwa:

1. Kami bertanggung jawab atas penyusunan dan penyajian laporan keuangan interim konsolidasian Perusahaan dan Entitas Anaknya;

2. Laporan keuangan interim konsolidasian Perusahaan dan Entitas Anaknya telah disusun dan disajikan sesuai dengan Standar Akuntansi Keuangan ("SAK”) di Indonesia; peraturan Otoritas Jasa Keuangan (“OJK"); dan Pedoman Penyajian dan Pengungkapan Laporan Emiten atau Perusahaan Publik yang dikeluarkan oleh OJK;

3. a. Semua informasi dalam laporan keuangan interim konsolidasian Perusahaan dan Entitas Anaknya telah dimuat secara lengkap dan benar;

b. Laporan keuangan interim konsolidasian Perusahaan dan Entitas Anaknya tidak mengandung informasi atau fakta material yang tidak benar, dan tidak menghilangkan informasi atau fakta material;

4. Kami bertanggung jawab atas sistem pengendalian internal dalam Perusahaan dan Entitas Anaknya. Demikian pernyataan ini dibuat dengan sebenarnya.

Declare that:

1. We are responsible for the preparation and

presentation o f the interim consolidated financial statements o f the Company and its Subsidiaries;

2. The interim consolidated financial statements o f the

Company and its Subsidiaries have been prepared and presented in accordance with Indonesian Financial

Accounting Standards ("SAK"); the Indonesian

Financial Services Authority (“OJK") regulations; and Guidance for Presentation and Disclosure o f Issuer of the Report o r Public Company released by OJK;

3. a. A ll information contained in the interim consolidated

financial statements o f the Company and its Subsidiaries have been completely and properly disclosed;

b. The interim consolidated financial statements o f the

Company and its Subsidiaries do not contain any improper material information or facts and do not omit material information o r facts;

4. We are responsible for the internal control system o f the

Company and its Subsidiaries. Thus, this statement is made truthfully.

Atas nama dan mewakili Dewan Direksi I For and on behalf o f the Board o f Directors Jakarta, 31 Juli 202VJuly 31, 2021

Hasmoro

Direktur Utama/President Director

Aristo S. Setiawidiaia Direktur/D/'rector

(4)

Kecuali Dinyatakan Lain) Unless Otherwise Stated)

30 Juni 2021/ Catatan/ 31 Desember 2020/

June 30, 2021 Notes December 31, 2020

ASET ASSETS

ASET LANCAR CURRENT ASSETS

Kas dan bank 572.794 2h,2i,4,30,31 864.577 Cash on hand and in banks

Piutang Accounts receivable

Usaha 2h,5,30,31 Trade

Pihak berelasi 2.602 29a 3.676 Related parties

Pihak ketiga - neto 1.790.926 1.051.759 Third parties - net

Aset kontrak 80.451 5 57.819 Contract assets

Lain-lain 2h,6,30,31 Others

Pihak berelasi 4.472 29b 9.650 Related parties

Pihak ketiga - neto 46.289 51.564 Third parties - net

Investasi aset keuangan 17.397 2h,2j,7 121.157 Investment of financial assets

Persediaan 72.900 2l,8 81.846 Inventories

Beban dibayar dimuka - neto 1.800 2m,9 4.497 Prepaid expenses - net

Uang muka 9.822 9 5.585 Advances

Aset lancar lainnya 1.784 272 Other current assets

Total aset lancar 2.601.237 2.252.402 Total current assets

ASET TIDAK LANCAR NON-CURRENT ASSETS

Estimasi tagihan restitusi pajak 2.745 14a 2.745 Estimated claims for tax refund

Uang muka Advances for purchase

pembelian aset tetap 419.821 11 195.863 of fixed assets

Aset pajak tangguhan 48.842 2s,14d 68.889 Deferred tax assets

Aset tetap - neto 4.005.987 2n,10 3.760.319 Fixed assets - net

Aset lain-lain - neto 94.570 2o,34b 75.036 Other assets - net

Total aset tidak lancar 4.571.965 4.102.852 Total non-current assets

TOTAL ASET 7.173.202 6.355.254 TOTAL ASSETS

Catatan atas laporan keuangan interim konsolidasian terlampir The accompanying notes to the interim consolidated

merupakan bagian yang tidak terpisahkan financial statements form an integral part of

(5)

30 Juni 2021/ Catatan/ 31 Desember 2020/

June 30, 2021 Notes December 31, 2020

LIABILITAS DAN EKUITAS LIABILITIES AND EQUITY

LIABILITAS JANGKA PENDEK CURRENT LIABILITIES

Utang bank jangka pendek 33.404 2h,16a,30,31 9.050 Short-term bank loans

Utang Accounts payable

Usaha 2h,12,30,31 Trade

Pihak berelasi 10.636 29c 6.428 Related parties

Pihak ketiga 356.346 289.440 Third parties

Lain-lain 2h,13,30,31 Others

Pihak berelasi 36.255 29d 26.032 Related parties

Pihak ketiga 541.262 404.460 Third parties

Utang pajak 295.447 2s,14b 295.551 Taxes payable

Akrual 26.175 2h,15,30,31 56.451 Accrued expenses

Liabilitas imbalan kerja karyawan Short-term employee

jangka pendek 152.677 2q,21a 96.268 benefits liabilities

Bagian liabilitas jangka panjang

yang jatuh tempo dalam Current portion

waktu satu tahun: of long-term liabilities:

Utang bank 137.794 2h,16b,30,31 253.951 Bank loans

Liabilitas kontrak 40.467 19 37.180 Contract liabilities

Liabilitas sewa 4.711 2x,20 4.759 Lease liabilities

Pembiayaan konsumen 13 2h,2x,18,30,31 88 Consumer finance

Total liabilitas jangka pendek 1.635.187 1.479.658 Total current liabilities

LIABILITAS JANGKA PANJANG NON-CURRENT LIABILITIES

Liabilitas jangka panjang setelah

dikurangi bagian yang jatuh Long-term liabilities

tempo dalam waktu satu tahun: net of current portion:

Utang bank 983.504 2h,16b,29,30 848.697 Bank loans

Liabilitas sewa 1.226 2x,20 3.704 Lease liabilities

Liabilitas kontrak 2.746 19 2.856 Contract liabilities

Utang obligasi - neto 445.413 2h,17, 29,30 445.194 Bonds payable - net

Liabilitas imbalan kerja karyawan Long-term

jangka panjang 203.089 2q,21b 192.968 employee benefits liability

Total liabilitas jangka panjang 1.635.978 1.493.419 Total non-current liabilities

TOTAL LIABILITAS 3.271.165 2.973.077 TOTAL LIABILITIES

Catatan atas laporan keuangan interim konsolidasian terlampir merupakan bagian yang tidak terpisahkan

dari laporan keuangan interim konsolidasian secara keseluruhan.

The accompanying notes to the interim consolidated financial statements form an integral part of these

(6)

Kecuali Dinyatakan Lain) Unless Otherwise Stated) 30 Juni 2021/ June 30, 2021 Catatan/ Notes 31 Desember 2020/ December 31, 2020 EKUITAS

Ekuitas yang dapat diatribusikan kepada pemilik entitas induk Modal saham - nilai nominal Rp100

per saham (nilai penuh) Modal dasar - 10.000.000.000 saham

Modal ditempatkan dan

EQUITY Equity attributable to owners

of the parent entity Share capital - Rp100 par value per share (full amount)

Authorized - 10,000,000,000 shares Issued and fully paid

-disetor penuh 2.978.000.000 saham 297.800 297.800 2,978,000,000 shares

Tambahan modal disetor 1.850.679 1b,23 1.850.679 Additional paid-in capital

Program opsi kepemilikan saham 73.688 2bb,22,34 73.688 Shares option program

Saham treasuri (166.660) 2cc,23 (60.592) Treasury shares

Selisih nilai transaksi dengan

pihak nonpengendali (513.983) 1b,1c (513.402)

Differences in value of transactions with non-controlling interests

Saldo laba

Telah ditentukan penggunaanya 4.000 24 2.000

Retained earnings Appropriated

Belum ditentukan penggunaanya 1.362.273 901.871 Unappropriated

Ekuitas yang dapat diatribusikan

kepada pemilik entitas induk 2.907.797 2.552.044

Equity attributable to owners of the parent entity

Kepentingan nonpengendali 994.240 23 830.133 Non-controlling interests

TOTAL EKUITAS 3.902.037 3.382.177 TOTAL EQUITY

TOTAL LIABILITAS DAN EKUITAS 7.173.202 6.355.254 TOTAL LIABILITIES AND EQUITY

(7)

pada Tanggal 30 Juni 2021 (Tidak Diaudit) (Disajikan dalam Jutaan Rupiah,

Kecuali Dinyatakan Lain)

June 30, 2021 (Unaudited)

(Expressed in Millions of Indonesian Rupiah, Unless Otherwise Stated)

Periode enam bulan yang berakhir pada tanggal 30 Juni/

Six-month period ended June 30,

Catatan/

2021 Notes 2020

PENDAPATAN NETO 3.098.249 25 1.732.161 NET REVENUES

BEBAN POKOK PENDAPATAN (1.439.778) 26 (1.014.801) COST OF REVENUES

LABA BRUTO 1.658.471 717.360 GROSS PROFIT

Beban usaha

Penghasilan lain-lain - neto

(674.590) 30.879 27 28 (511.538) 30.281 Operating expenses Other income - net

LABA USAHA 1.014.760 236.103 OPERATING INCOME

Biaya keuangan dan administrasi bank Penghasilan keuangan

(70.730) 11.633

(63.795) 20.273

Finance costs and bank administration Finance income

LABA SEBELUM

BEBAN PAJAK PENGHASILAN 955.663 192.581

INCOME BEFORE INCOME TAX EXPENSE

Beban pajak penghasilan Kini Tangguhan (217.885) (23.094) 2s,14c 2s,14c (58.227) (101)

Income tax expense Current Deferred

BEBAN PAJAK

PENGHASILAN - NETO (240.979) 2s,14c (58.328) INCOME TAX EXPENSES - NET

LABA NETO PERIODE BERJALAN 714.684 134.253 NET INCOME FOR THE PERIOD

RUGI KOMPREHENSIF LAIN Pos-pos yang tidak akan

direklasifikasikan ke laba rugi Pengukuran kembali liabilitas

imbalan kerja karyawan Pajak penghasilan terkait

(13.851) 3.047 21 14d (8.255) 1.846

OTHER COMPREHENSIVE LOSS Item that will not be reclassified to profit or loss

Re-measurements on liabilities for employee benefits

Related income tax

RUGI KOMPREHENSIF LAIN PERIODE BERJALAN,

SETELAH PAJAK (10.804) (6.409)

OTHER COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX

TOTAL PENGHASILAN KOMPREHENSIF PERIODE

BERJALAN 703.880 127.844

TOTAL COMPREHENSIVE INCOME FOR THE PERIOD

merupakan bagian yang tidak terpisahkan financial statements form an integral part of these

(8)

pada Tanggal 30 Juni 2021 (Tidak Diaudit) (Disajikan dalam Jutaan Rupiah,

Catatan/

2021 Notes 2020

LABA NETO PERIODE BERJALAN

YANG DAPAT DIATRIBUSIKAN NET INCOME FOR THE PERIOD

KEPADA: ATTRIBUTABLE TO:

Pemilik entitas induk 544.655 104.239 The owners of parent entity

Kepentingan nonpengendali 170.029 30.014 Non-controlling interests

Total 714.684 134.253 Total

TOTAL PENGHASILAN KOMPREHENSIF

PERIODE BERJALAN YANG DAPAT DIATRIBUSIKAN KEPADA:

TOTAL COMPREHENSIVE INCOME FOR THE PERIOD ATTRIBUTABLE TO:

Pemilik entitas induk 535.920 Kepentingan nonpengendali 167.960

99.209 Owners of the parent entity

28.635 Non-controlling interests

Total 703.880 127.844 Total

LABA PER SAHAM (dalam Rupiah penuh) Yang diatribusikan kepada

pemilik entitas induk

Dasar 184,54 23 35,09

EARNING PER SHARE (in full Rupiah) Attributable to equity holders of the parent entity

Basic

Dilusian 182,45 23 34,57 Diluted

5

(9)

Ekuitas yang dapat diatribusikan kepada pemilik entitas induk/ Equity attributable to owners o f the parent entity

Tambahan modal disetor/ Additional paid- in capital Program opsi kepemilikan saham/ Shares option program

Selisih nilai transaksi dengan pihak Saldo laba/ Retained earnings Kepentingan nonpengendali/ Non-controlling interests Catatan/ Notes Modal saham/ Share capital Saham treasuri/ Treasury shares nonpengendali/ Transactions with non-controlling interests Telah ditentukan penggunaannya/ Appropriated Belum ditentukan penggunaannya/ Unappropriated Total/Total Total ekuitas/ Total equity

Saldo 31 December 2019 297.300 1.831.179 - 53.387 (519.232) 1.000 483.575 2.147.209 617.225 2.764.434 Balance as o f Decem ber 31, 2019

P e n ye su a ia n tra n sisi a ta s p en erap a n

s ta n d a r a ku n ta n si baru - P S A K 71 (828 ) (828) (828)

T ra n sition a d ju s tm e n t o f a p p lyin g n e w a c c o u n tin g sta n d a rd s - P S A K 71

Saldo 1 Januari 2020 297.300 1.831.179 - 53.387 (519.232) 1.000 482.747 2.146.381 617.225 2.763.606 Balance as o f January 1, 2020

D ivide n 32 (3 5.570) (35.570) (1 3 .2 1 8) (48.788) D iv id e n d s

P em be lia n K em ba li sa ha m 23 (28.111) (28.111) (28.111) B u y b a c k o f s h a re s

L a b a n eto p e rio d e b erjalan 1 0 4 .23 9 1 0 4 .23 9 3 0 .0 1 4 1 3 4 .25 3 N e t in c o m e fo r the p e rio d

R u g i ko m p re h e n s if lain p eriod e b erjalan (5.030) (5.030) (1.379) (6.409) O th e r c o m p re h e n s iv e lo ss fo r th e p e rio d

P e m b e n tu ka n ca d a n g a n um u m 24 1 .000 (1.000) A p p ro p ria te fo r g e n e ra l re v e rs e s

S e lisih nilai tra n s a k s i d en ga n

p ih a k n on p e n g e n d a li 3.991 3.991 (6.856) (2.865)

D iffe re n c e s in v a lu e o f tra n sa ctio n s w ith n o n -c o n tro llin g in te re sts

O p s i p e n ye rta a n sa ha m 22 1 3 .2 2 6 1 3 .2 2 6 1 3.2 26 S h a re s O p tio n

P e n a m b a h a n m odal d ise to r

o le h ke pe ntin g an n o n p e n g e n d a li 6 7 .0 8 9 6 7 .0 8 9

'A d d itio n a l p a id -in c a p ita l b y n o n -c o n tro llin g in te re sts

Saldo 30 Juni 2020 297.300 1.831.179 (28.111) 66.613 (515.241) 2.000 545.386 2.199.126 692.875 2.892.001 Balance as o f June 30, 2020

Saldo 1 Januari 2021 297.800 1.850.679 (60.592) 73.688 (513.402) 2.000 901.871 2.552.044 830.133 3.382.177 Balance as o f January 1, 2021

Dividen 32 (73.518) (73.518) (3 2 .8 4 0) (1 0 6.3 58 ) D iv id e n d s

P em be lia n ke m b a li sa ha m 23 (1 0 6.0 68 ) (1 0 6.0 68 ) (1 0 6.0 68 ) B u y b a c k o f sh ares

L ab a neto p e rio d e b erjalan 5 4 4 .6 5 5 5 4 4 .6 5 5 1 7 0 .02 9 7 1 4 .6 8 4 N e t in c o m e fo r the p e rio d

R u g i ko m p re h e n s if lain

p e rio d e b erjalan (8.735) (8.735) (2.069) (10.804)

O th e r c o m p re h e n s iv e lo ss fo r the p e rio d

P e m b e n tu ka n ca d a n g a n um u m 24 2 .0 0 0 (2.000) A p p ro p ria te f o r g e n e ra l re v e rs e s

S e lisih nilai tra n s a k s i d en ga n

p ih a k n on p e n g e n d a li (581) (581) (10.950) (11.531)

D iffe re n c e s in v a lu e o f tra nsa ctio ns w ith n o n -c o n tro llin g in te re sts

P e n a m b a h a n m odal d ise to r

o leh ke pe ntin g an n o n p e n g e n d a li 3 9 .9 3 7 3 9 .9 3 7

A d d itio n a l p a id -in c a p ita l b y n o n -c o n tro llin g in te re sts

Saldo 30 Juni 2021 297.800 1.850.679 (166.660) 73.688 (513.983) 4.000 1.362.273 2.907.797 994.240 3.902.037 Balance as o f June 30, 2021

(10)

(Disajikan dalam Jutaan Rupiah, Kecuali Dinyatakan Lain)

Catatan/

2021 Notes 2020

ARUS KAS DARI CASH FLOWS FROM

AKTIVITAS OPERASI OPERATING ACTIVITIES

Penerimaan kas dari pasien 2.254.951 2.005.307 Cash receipts from patients

Pembayaran kas kepada Cash paid to suppliers

pemasok dan pihak lainnya (1.118.661) (810.170) and other party

Pembayaran kas kepada karyawan (695.809) (647.762) Cash paid to employees

Penerimaan kas lain-lain 30.946 33.112 Cash receipts from other income

Kas diperoleh dari operasi 471.427 580.487 Cash generated from operations

Penerimaan penghasilan keuangan 11.633 20.273 Finance income received

Pembayaran biaya keuangan Finance costs and

dan administrasi bank (74.285) (76.047) bank administration paid

Pembayaran pajak penghasilan badan (185.088) (105.327) Corporate income taxes paid

Kas Neto Diperoleh dari Net Cash Provided by Operating

Aktivitas Operasi 223.687 419.386 Activities

AKTIVITAS INVESTASI INVESTING ACTIVITIES

Penerimaan hasil penjualan aset tetap 63 10 358 Proceeds from sale of fixed assets

Perolehan aset lain-lain (9.306) (12.953) Acquisitions of other assets

Uang muka pembelian aset tetap (273.209) (87.983) Advances for acquisition o f fixed assets

Perolehan aset tetap (252.804) (241.417) Acquisitions of fixed assets

Pelepasan investasi Disposal of

aset keuangan 103.759 - investment of financial assets

Kas Neto Digunakan untuk Net Cash Used in

Aktivitas Investasi (431.497) (341.995) Investing Activities

AKTIVITAS PENDANAAN FINANCING ACTIVITIES

Utang bank Bank loans

Penerimaan pinjaman 137.677 151.556 Proceeds from loans

Pembayaran pinjaman (94.673) (190.633) Repayments of loans

Perolehan saham treasuri (106.068) (28.111) Acquisition of treasury shares

Penerimaan (pembayaran) atas Receipts (payments)

utang dan piutang of due to and due from

pihak berelasi - neto 19.608 (3.164) related parties - net

Pembayaran utang sewa (2.671) - Payment of lease liability

Pembayaran utang Payments of

pembiayaan konsumen (75) (68) consumer finance

Pembagian dividen tunai kepada Payments of cash dividends to

kepentingan nonpengendali (37.771) (8.798) subsidiaries non-controlling interests

Kas Neto Digunakan untuk Net Cash used in

Aktivitas Pendanaan (83.973) (79.218) Financing Activities

(11)

INTERIM KONSOLIDASIAN (lanjutan) Untuk Periode Enam Bulan yang Berakhir pada

Tanggal 30 Juni 2021 (Tidak Diaudit) (Disajikan dalam Jutaan Rupiah,

CASH FLOWS (continued) For the Six-Month Period Ended

KENAIKAN NETO KAS DAN BANK

2021 (291.783) Catatan/ Notes 2020 (1.827) NET INCREASE IN CASH ON HAND AND IN BANKS

KAS DAN BANK PADA

AWAL PERIODE 864.577 593.255

CASH ON HAND AND IN BANKS A T BEGINNING OF PERIOD

KAS DAN BANK PADA

AKHIR PERIODE 572.794 4 591.428

CASH ON HAND AND IN BANKS AT END OF PERIOD

Informasi atas aktivitas yang tidak mempengaruhi Information of non-cash activities is disclosed in Note 35.

arus kas diungkapkan dalam Catatan 35.

(12)

(Disajikan dalam Jutaan Rupiah, _________ kecuali Disebutkan Lain)__________

Unless Otherwise Stated)

1. UMUM

a. Pendirian Perusahaan

PT Medikaloka Hermina Tbk (“Perusahaan”) didirikan berdasarkan Akta Notaris Imam Santoso, S.H., No. 5 tanggal 7 Mei 1999. Akta

pendirian Perusahaan telah mendapat

pengesahan dari Menteri Kehakiman dan Hak Asasi Manusia (sekarang menjadi Menteri Hukum dan Hak Asasi Manusia) Republik Indonesia dalam Surat Keputusan No. C-17517 HT.01.01 .TH.99 tanggal 12 Oktober 1999 serta

telah diumumkan dalam Berita Negara

Republik Indonesia No. 82, Tambahan

No. 6136 tanggal 13 Oktober 2000.

Anggaran Dasar Perusahaan telah mengalami beberapa kali perubahan, terakhir berdasarkan Akta Berita Acara Rapat Umum Pemegang Saham (“RUPS”) yang diaktakan dengan akta Notaris Christina Dwi Utami, S.H., M.H., M.kn No. 03 tanggal 2 Juni 2021 mengenai:

- Persetujuan untuk melakukan pemecahan

nilai nominal saham Perusahaan, dengan rasio 1:5, semula sebesar Rp100 per lembar saham menjadi sebesar Rp20 per lembar saham

Perubahan ini telah mendapat persetujuan dari Menteri Hukum dan Hak Asasi Manusia Republik Indonesia tanggal 15 Juni 2021

dengan Surat Keputusannya No. AHU-

AH.01.03-0376045

Perusahaan adalah pemilik Rumah Sakit Hermina Jatinegara dan beralamat di Jalan Jatinegara Barat No. 126, Jakarta Timur. Ijin penyelenggaraan rumah sakit Perusahaan berdasarkan Surat Keputusan Kepala Dinas Penanaman Modal dan Pelayanan Terpadu Satu Pintu Provinsi Daerah Khusus Ibukota

Jakarta No. 18/2.5/31/-1.77/2017 tanggal

22 Juni 2017 yang berlaku sampai dengan 22 Juni 2022. Perusahaan memulai kegiatan operasionalnya pada tahun 1985. Perusahaan merupakan bagian dari grup usaha Hermina.

Berdasarkan Pasal 3 Anggaran Dasar

Perusahaan, maksud dan tujuan Perusahaan adalah berusaha dalam bidang jasa kesehatan.

Perusahaan dan entitas anak (bersama-sama disebut Grup) tidak memiliki entitas induk dan

entitas induk terakhir yang memiliki

pengendalian atas Perusahaan dan Entitas Anak.

1. GENERAL

a. The Company’s Establishment

PT Medikaloka Hermina Tbk (“the Company") was established based on Notarial Deed of Imam Santoso, S.H., No. 5 dated May 7, 1999. The Deed of Establishment has been approved by Minister of Justice and Human Rights (recently known as the Minister of Law and Human Rights) of Republic of Indonesia

by virtue of his decree No. C-17517

HT.01.01.TH.99 dated October 12, 1999 and was published in the State Gazette of the Republic of Indonesia No. 82, Supplement No. 6136 dated October 13, 2000.

The Company’s Articles of Association have been amended several times, most recently based on General Shareholders Meeting which notarized by Notary Deed of Christina Dwi Utami S.H, M.H., M.Kn No. 03 dated June 2, 2021, regarding:

- Approval to do stock split of the Company shares with a ratio of 1:5, from RpW0,00 per share to Rp20.00 per share.

The amendments were approved by the Minister of Law and Human Rights of Republic of Indonesia dated June 15, 2021 by its decree No. AHU-AH.01.03-0376045

The Company is the owner of Hermina Hospital Jatinegara addressed at Jalan Jatinegara Barat No. 126, East Jakarta. Operating license of the Company's hospital is based on the Decision Letter of the Head of Capital Investment and One-Stop Service Department of Special Capital City Region Province of Jakarta. No. 18/2.5/31/-1.77/2017 dated June 22, 2017 which is valid through June 22, 2022. The Company started its commercial operations in 1985. The Company is part of the Hermina business group.

In accordance with Article 3 of the Company’s Articles of Association, the Company’s scope of activities is healthcare services.

The Company and its subsidiaries (collectively referred to herein as the Group) do not have parent entity nor ultimate parent entity which has the control over the Company and its Subsidiaries.

(13)

(Disajikan dalam Jutaan Rupiah,

_____________kecuali Disebutkan Lain)_____________ 1. UMUM (lanjutan)

b. Penawaran Umum Efek Perusahaan dan Penerbitan Obligasi

Pada tanggal 4 Mei 2018, Perusahaan

memperoleh pernyataan efektif dari Ketua

Otoritas Jasa Keuangan (“OJK”) dalam

suratnya No. S-45/D.04/2018 untuk melakukan

penawaran umum perdana sebanyak

446.110.000 saham dengan nilai nominal Rp100 (Rupiah penuh) per saham kepada masyarakat melalui Bursa Efek Indonesia dengan harga penawaran perdana sebesar Rp3.700 (Rupiah penuh) per saham.

Sejak tanggal 16 Mei 2018, Perusahaan mencatatkan saham hasil penawaran tersebut pada Bursa Efek Indonesia.

Jumlah saham yang diterbitkan sehubungan dengan penawaran umum perdana adalah 446.110.000 lembar saham (termasuk hasil konversi obligasi (wajib) konversi sejumlah 94.730.000 lembar).

Berdasarkan Berita Acara Rapat Umum Pemegang Saham Luar Biasa (RUPSLB) yang diaktakan dengan akta No. 40 pada tanggal 10 November 2020 oleh Notaris Christina Dwi Utami, SH, Mhum, Mkn. para pemegang saham menyetujui peningkatan jumlah saham yang ditempatkan dan disetor Perusahaan dari 2.973.000.000 saham (nilai penuh) menjadi sebanyak-banyaknya 3.181.110.000 saham (nilai penuh) yang diambil dari saham dalam portepel. Perubahan ini telah diterima dan dicatat di dalam Sistem Administrasi Badan Hukum di Kementerian Hukum dan Hak Asasi Manusia melalui surat keputusan Nomor AHU- AH.01.03-0409349 tanggal 19 November 2020. Pada tanggal 22 Desember 2020, Perusahaan memperoleh Surat Persetujuan Pencatatan Efek nomor S-08045/BEI.PP3/12-2020 dari Bursa Efek Indonesia terkait Permohonan Pencatatan Saham Tambahan Dalam Rangka Penambahan Modal Tanpa Hak Memesan Efek

Terlebih Dahulu (“PMTHMETD:) untuk

menerbitkan saham baru yang dilaksanakan melalui PMTHMETD sebanyak 5.000.000 saham (nilai penuh) dengan nilai nominal Rp100 (rupiah penuh) per saham dengan harga pelaksanaan Rp4.000 (rupiah penuh) per saham.

Pada tanggal 31 Desember 2020, jumlah saham yang tercatat di Bursa Efek Indonesia adalah sebanyak 2.978.000.000 saham dengan nilai nominal Rp100 (rupiah penuh) per saham.

1. GENERAL (continued)

b. The Company’s Public Offering and

Issuance of Bonds

On May 4, 2018, the Company received the effective statement from the Chairman of the Financial Services Authority (“OJK”) in its Decision Letter No. S-45/D.04/2018 to offer its 446,110,000 shares to the public with par value of Rp100 (full amount) per share through the Indonesia Stock Exchange, at an initial offering price of Rp3,700 (full amount) per share.

On May 16, 2018, the Company has listed the offered shares on the Indonesia Stock Exchange.

The number of shares issued in relation with the initial public offering are 446,110,000 shares (including the conversion of (mandatory) convertible notes equivalent to 94,730,000 shares).

Based on the minutes of the extraordinary meeting of shareholders which were notarized under deed No. 40 dated November 10, 2020 of Notary Christina Dwi Utami, S.H., M.hum., M.kn., the Company’s shareholders approved the increase the number of issued and fully paid capital stock from 2,973,000,000 shares (full amount) to maximum 3,181,110,000 shares (full amount) from its authorized capital stock. The amendment has been received by and recorded in the Administration System of Legal Entities through letter of the Ministry of Justice and Human Rights based on its Decree No. AHU-AH.01.03-0409349 dated November 19, 2020.

On December 22, 2020, the Company obtained approval from Indonesia Stock Exchange authority in his letter No.S-08045/BEI.PP3/12- 2020 to conduct the Non Preemptive Rights

Issuance of Shares (“PMTHMETD") of

5,000,000 shares (full amount) with par value of Rp100 (full amount) per share at the offering price of Rp4,000 (full amount) per share.

As of December 31, 2020, the total number of

shares listed in the Indonesia Stock Exchange are 2,978,000,000 shares with par value of Rp100 (full amount) per share.

(14)

(Disajikan dalam Jutaan Rupiah, _____________ kecuali Disebutkan Lain)__________

1. UMUM (lanjutan)

1. GENERAL (continued)

b. Penawaran Umum Efek Perusahaan dan Penerbitan Obligasi (lanjutan)

Pada tanggal 31 Agustus 2020, Perusahaan

memperoleh Surat Pemberitahuan Efektif

Pernyataan Pendaftaran No. S-233/D.04/2020 dari Dewan Komisioner OJK sehubungan

dengan Penawaran Umum Berkelanjutan

Obligasi Berkelanjutan I Medikaloka Hermina Tahap I Tahun 2020 dengan nilai nominal sebesar Rp425.500 untuk seri A dengan tingkat bunga tetap sebesar 8,00% dan nilai nominal Rp21.000 untuk seri B dengan tingkat bunga tetap sebesar 8,50%. Obligasi ini akan jatuh tempo masing-masing pada bulan September 2023 dan September 2025

b. The Company’s Public Offering and

Issuance of Bonds (continued)

On August 31, 2020, the Company obtained the Notice of Effectivity from the Board of Commissioners of OJK in its letter No. S- 233/D.04/2020 for its Public Offering of Sustainable Continuity Bonds I Medikaloka Hermina Tranche I Year 2020 with face value of Rp425,500 for series A which bear interest at the fixed rate of 8.00% and face value of Rp21,000 for series B which bear interest at the fixed rate of 8.50%. The bonds will mature on September 2023 and September 2025, respectively.

Obligasi tersebut telah tercatat di Bursa Efek The bonds were registered in Indonesia Stock

Indonesia pada tanggal 9 September 2020 Exchange on September 9, 2020.

c. Entitas Anak c. Subsidiaries

Pada tanggal 30 Juni 2021 dan 31 Desember As of June 30, 2021 and December 31, 2020,

2020, Perusahaan mempunyai kepemilikan the Company has direct or indirect ownership in

langsung maupun tidak langsung pada Entitas the following Subsidiaries:

Anak sebagai berikut:

Tempat Ruang Lingkup Usaha/ Tahun Pendirian/ Tahun Operasi Komersial/ Y ear of Persentase Kepemilikan Grup/ Percentage of Ownership o f Group

Total Aset Sebelum Eliminasi/ Total Assets Before

Elimination Entitas Anak/ Subsidiaries Kedudukan/ Domicile Scope o f Activities Y e ar o f Establishment Commercial Operations 2021 2020 2021 2020 Langsung/Direct PT M e d ika lo ka Inte rn usa

(M Internusa) J a ka rta R u m a h S a kit / H o s p ita l 1989 1989 6 5,5 0% 6 5,5 0% 4 8 2 .6 1 0 495.961 PT M e d ika lo ka S e ja h te ra

(M S e ja h te ra ) Bekasi R u m a h S a kit / H o s p ita l 1996 1997 7 4,0 0% 7 4,0 0% 4 5 4 .0 8 5 4 0 7 .9 1 4 PT M e d ika lo ka H u sad a

(M H u sad a ) D e p o k R u m a h S a k it / H o s p ita l 2 00 0 2 00 0 7 9,7 5% 7 8,7 5% 2 3 1 .5 2 2 2 1 4 .5 2 5 PT M e d ika lo ka D aan M o g ot

(M D a a n M ogot) J a ka rta R u m a h S a k it / H o s p ita l 2001 2 00 2 7 2,0 0% 7 2,0 0% 2 9 4 .3 8 5 268.321

PT M e d ika lo ka B og o r (M Bogor) B ogor R u m a h S a kit / H o s p ita l 2001 2 00 2 8 3,7 5% 8 3,7 5% 1 5 4 .92 2 1 30 .98 5 PT M e d ika lo ka M itra P aste ur

(M M Pasteur) J a ka rta In ve sta si / In v e s tm e n t 2 0 0 3 6 5,0 0% 6 4,1 7% 1 5.2 53 1 5.6 07 PT M e d ika lo ka P aste ur

(M Pasteur) B andung R u m a h S a k it / H o s p ita l 2 0 0 3 2 0 0 4 1 8,25% 1 6,75% 1 8 6 .36 3 1 49 .94 4 PT M e d ika lo ka M a la ng (M

M alang) M a la ng R u m a h S a kit / H o s p ita l 2 0 0 4 2 0 0 5 6 5,5 0% 6 5,5 0% 1 3 3 .88 0 9 8 .4 7 8 PT M e d ika lo ka M itra

P an d an aran

(M M P an d an aran ) J a ka rta In ve sta si / In v e s tm e n t 2 0 0 4 7 0,0 0% 7 0,0 0% 7.181 6.771 PT M e d ika lo ka P an d an aran

(M P an d an aran ) S em a ra n g R u m a h S a kit / H o s p ita l 2 0 0 4 2 0 0 4 2 6,7 9% 2 6,4 3% 1 1 3 .96 2 9 1 .1 7 6 PT M e d ika lo ka M itra A rc a m a n ik

(M M A rca m a nik) J a ka rta In ve sta si / In v e s tm e n t 2 00 8 6 8,5 7% 6 5,7 1% 2 0 .6 7 4 2 1 .5 4 3 PT M e d ika lo ka M itra S u ka b um i

(M M S uka b um i) J a ka rta In ve sta si / In v e s tm e n t 2 00 6 7 0,7 8% 6 8,8 3% 1 1.1 45 11.571 PT M e d ika lo ka S u ka b u m i

(M S uka b um i) S u ka b um i R u m a h S a kit / H o s p ita l 2 00 6 2 00 7 1 6,00% 1 6,00% 1 0 7 .35 3 1 00 .79 7 PT M e d ika lo ka M itra G ra nd

B eka si (M M G ra nd Bekasi) J a ka rta In ve sta si / In v e s tm e n t 2 0 0 7 6 8,9 8% 6 8,1 4% 1 8.4 50 1 9.2 94 PT M e d ika lo ka M itra T a n g e ra n g

(15)

(Disajikan dalam Jutaan Rupiah, Unless Otherwise Stated)

____________ kecuali Disebutkan Lain)_____________ _______________________________________________

1. UMUM (lanjutan) 1. GENERAL (continued)

c. Entitas Anak (lanjutan) c. Subsidiaries (continued)

Entitas Anak/ Subsidiaries Tempat Kedudukan/ Domicile Ruang Lingkup Usaha/ Scope of Activities Tahun Pendirian/ Year of Establishment Tahun Operasi Komersial/ Year of Commercial Operations Persentase Kepemilikan Grup/ Percentage of Ownership of Group

Total Aset Sebelum Eliminasi/ Total Assets Before

Elimination 2021 2020 2021 2020 Langsung (lanjutan)/D/rect (continued) PT M e d ika lo ka T a n g e ra n g (M T a n g e ra n g ) T a n g e ra n g R u m a h S a k it / H o s p ita l 2 00 6 2 00 8 2 0,7 5% 2 0,7 5% 238.151 2 0 3 .1 5 3 PT M e d ika lo ka G ra n d B e k a s i (M G ra nd Bekasi) B eka si R u m a h S a k it / H o s p ita l 2 00 8 2 0 0 9 2 6,2 5% 2 5,2 5% 2 6 7 .5 5 6 2 3 2 .8 2 2 PT M e d ika lo ka M itra P alem b a ng

(M M P alem b a ng ) Ja karta Inve stasi / In v e s tm e n t 2 01 0 7 0,2 7% 6 9,3 7% 2 6 .8 3 7 2 7 .3 7 9 PT M e d ika lo ka A rc a m a n ik

(M A rca m a nik) B andung

R u m a h S a k it /

H o s p ita l 2 00 8 2 01 0 12,25% 1 1,25% 2 0 0 .2 6 0 1 3 0 .43 2 PT M e d ika lo ka M itra C ip u ta t

(M M C iputat) Ja karta In v e s ta s i / In v e s tm e n t 2 01 0 6 9,5 5% 6 8,6 4% 2 1 .1 7 7 2 1 .0 8 6 PT M e d ika lo ka M itra G ala xy

(M M G alaxy) Ja karta In v e s ta s i / In v e s tm e n t 2 01 0 6 5,0 0% 6 5,0 0% 1 1.7 78 1 2.3 80 PT M e d ika lo ka G a la xy (M G alaxy) B eka si R u m a h S a k it / H o s p ita l 2 00 2 2 01 0 5 ,00% 5 ,00% 1 26 .42 3 1 1 2 .82 7 PT M e d ika lo ka M itra

C ile u n g s i (M M C ileu ng si) Ja karta In v e s ta s i / In v e s tm e n t 2011 5 9,2 3% 5 7,6 9% 2 9 .9 5 3 30.691 PT M e d ika lo ka C ip u ta t (M C iputat) T a n g e ra n g R u m a h S a k it / H o s p ita l 2 01 0 2011 2 7,5 0% 2 7,5 0% 1 71 .00 8 1 3 9 .71 0 PT M e d ika lo ka P alem b a ng (M P alem b a ng ) P a lem b a ng R u m a h S a k it / H o s p ita l 2 01 0 2011 3 7,2 5% 3 7,2 5% 1 90 .14 5 1 7 7 .77 5 PT M e d ika lo ka M itra B a n yu m a n ik (M M B an yu m an ik) Ja karta In v e s ta s i / In v e s tm e n t 2 0 1 3 6 3,4 6% 6 3,4 6% 3 3 .2 0 2 3 3 .4 8 5 PT M e d ika lo ka M itra S olo

(M M S olo) Ja karta In v e s ta s i / In v e s tm e n t 2 0 1 3 5 6,3 6% 5 6,3 6% 3 0 .4 7 9 3 0 .7 3 5 PT M e d ika lo ka C ile u n g s i

(M C ileu ng si) B og o r

R u m a h S a k it /

H o s p ita l 2011 2 0 1 3 3 0,2 5% 2 9,7 5% 1 48 .04 0 1 3 3 .19 9 PT M e d ika lo ka M itra S erpo ng

(M M S erpo ng ) J a ka rta In v e s ta s i / In v e s tm e n t 2 0 1 3 7 3,5 3% 7 3,5 3% 1 9.1 48 1 8.9 05 PT M e d ika lo ka B a n y u m a n ik (M B an yu m an ik) S e m a ra n g R u m a h S a k it / H o s p ita l 2 0 1 3 2 0 1 4 19,00% 1 8,50% 1 14 .62 7 1 0 3 .52 4 PT M e d ika L o k a C iru a s (M C iruas) S era n g R u m a h S a k it / H o s p ita l 2 0 1 4 2 0 1 4 6 6,7 0% 6 6,2 0% 130.441 1 2 5 .23 8 PT M e d ika L o k a Y o g ya (M Y og ya ) Y o g y a k a rta R u m a h S a k it / H o s p ita l 2 0 1 4 2 0 1 5 5 9,0 0% 5 9,0 0% 91.001 8 4 .9 4 4 PT M e d ika L o k a P ad a ng (M Padang) Padang R u m a h S a k it / H o s p ita l 2 0 1 4 2 01 8 6 7,5 0% 6 7,5 0% 1 30 .54 0 1 1 7 .40 8 PT M e d ika L o k a Bitung (M Bitung) T a n g e ra n g R u m a h S a k it / H o s p ita l 2 0 1 4 2 01 6 5 8,6 1% 5 8,6 1% 1 74 .40 7 142.861 PT M e d ika L o k a P urw o ke rto

(M P urw oke rto ) P u rw o ke rto

R u m a h S a kit / H o s p ita l 2 0 1 5 2 0 1 7 6 2,8 5% 6 2,8 5% 1 27 .97 8 1 1 4 .66 3 PT M e d ika L o k a S a m a rin d a (M S a m a rin d a ) S a m a rin d a R u m a h S a kit / H o s p ita l 2 01 6 2 01 8 8 3,0 0% 8 1,5 0% 1 39 .46 9 1 2 8 .75 3 PT M e d ika L o k a M a ka ssa r (M M a ka ssar) M a ka ssa r R u m a h S a kit / H o s p ita l 2 0 1 4 2 01 6 5 6,5 0% 5 6,5 0% 1 39 .20 9 1 1 9 .57 9 PT M e d ika L o k a B alikpa p an (M B alikpa p an ) B alikpa p an R u m a h S a kit / H o s p ita l 2 0 1 5 2 0 1 7 6 1,5 0% 6 1,5 0% 1 36 .68 8 1 1 7 .80 4 PT M e d ika L o k a M edan (M M edan) M edan R u m a h S a kit / H o s p ita l 2 0 1 4 2 0 1 7 6 6,5 0% 6 6,0 0% 1 57 .94 9 1310.121 PT M e d ika L o k a P od o m o ro (M P od o m oro) Ja karta R u m a h S a kit/ H o s p ita l 2 0 1 7 2 0 1 7 8 5,5 0% 8 5,3 8% 1 85 .56 4 172.641 PT M e d ika Loka Ja ka b a rin g

(M Ja ka b a rin g ) P a lem b a ng R u m a h S a kit / H o s p ita l 2 0 1 7 2 01 8 5 8,5 0% 5 8,0 0% 1 40 .64 0 1 2 4 .99 5 PT M e d ika Loka K a ra w a n g (M K ara w a n g ) K araw a n g R u m a h S a kit / H o s p ita l 2 0 1 7 2 02 0 7 3,2 5% 9 9,0 0% 218.711 1 8 7 .47 2 PT M e d ika Loka K e n d a ri (M K en d ari) K en d ari R u m a h S a kit / H o s p ita l 2 0 1 7 2 0 1 9 8 0,5 0% 8 0,4 0% 1 03 .87 3 100.221

(16)

(Disajikan dalam Jutaan Rupiah, _________ kecuali Disebutkan Lain)__________

1. UMUM (lanjutan) 1. GENERAL (continued)

c. Entitas Anak (lanjutan) Subsidiaries (continued)

Persentase Total Aset Sebelum Tahun Kepemilikan Grup/ Eliminasi/ Operasi Percentage o f Total Assets Before

Ruang Tahun Komersial/ Ownership Elimination

Tempat Lingkup Usaha/ Pendirian/ Year of o f Group

Entitas Anak/ Kedudukan/ Scope of Year of Commercial

2021 2020 2021 2020

Subsidiaries Domicile Activities Establishment Operations Langsung (lanjutan)/D/recf

(continued)

PT M e d ika Loka P eka n ba ru R u m a h S a kit /

7 9,0 0% 7 9,5 5%

(M P eka n ba ru ) P eka n ba ru H o s p ita l 2 01 7 2 0 1 9 1 21 .06 3 1 0 9 .65 0 PT M e d ika Loka K u ta b u m i R u m a h S a kit /

9 9,0 0% 9 9,0 0%

(M K uta bu m i) T a n g e ra n g H o s p ita l 2 01 7 2 02 0 1 24 .63 5 1 1 3 .42 4 PT M e d ika Loka Mitra J a s a & P erd a g a n g a n /

F a rm a si (M M Fa rm a si) J a k a rta S e rv ic e & Tra d ing 2 0 1 6 2 0 1 8 9 9,0 0% 9 9,0 0% 1 1.7 68 1 1.3 42 PT M e d ika Loka P en d idikan

P elatihan J a s a P en d id ika n /

(M P en d id ika n P elatihan) J a ka rta E d u c a tio n S e rvice 2 01 7 2 0 1 8 9 9,0 0% 9 9,0 0% 2 7 .2 3 7 2 2 .5 1 3 PT M e d ika Loka In v e s ta m a J a s a & P erd a g a n g a n /

(M In ve sta m a ) J a k a rta S e rv ic e & Tra d ing 2 01 7 2 0 1 8 7 5,0 0% 7 5,0 0% 1 33 .62 0 1 0 0 .65 5 PT M e d ika Loka C ile g o n R u m a h S a kit /

(M C ilegon) B an ten H o s p ita l 2 0 1 8 9 9,0 0% 9 9,0 0% 8 3 .5 2 6 2 8 .6 3 4 PT M e d ika Loka D e n p a sa r R u m a h S a kit /

(M D e np a sar) D e n p a sa r H o s p ita l 2 0 1 6 9 9,0 0% 9 9,0 0% 9 00 9 00 PT M e d ika L oka A m b on R u m a h S a kit /

(M A m b on ) A m b on H o s p ita l 2 0 1 8 9 9,0 0% 9 9,0 0% 1 6.3 40 1 6.3 40 PT M e d ika L oka C ib itu ng R u m a h S a kit /

(M C ib itu ng ) B eka si H o s p ita l 2 0 1 8 9 9,0 0% 9 9,0 0% 93.721 5 7 .2 7 0 PT M e d ika L oka M an ad o R u m a h S a kit /

(M M anado) M a n ad o H o s p ita l 2 0 1 4 8 7,2 5% 9 9,9 1% 1 10 .76 6 1 0 7 .94 6 PT M e d ika L oka C iaw i R u m a h S a kit /

(M C iaw i) B o g o r H o s p ita l 2 0 1 8 9 9,0 0% 9 9,0 0% 9 67 9 00

PT M e d ika L oka Kupang R u m a h S a kit /

(M Kupang) Kup a ng H o s p ita l 2 0 1 8 9 9,0 0% 9 9,0 0% 9 32 9 24

PT M e d ika L oka L am pung R u m a h S a kit /

(M L am pung) L am pu ng H o s p ita l 2 0 1 8 2 02 0 6 6,2 5% 6 6,5 0% 1 30 .98 0 1 1 0 .94 4 PT M e d ika Loka P eka lo ng a n

P eka lo ng a n R u m a h S a kit /

(M P eka lo ng a n) H o s p ita l 2 0 1 9 2 0 1 9 8 2,9 1% 8 2,3 2% 6 9 .1 2 0 6 2 .0 1 9 PT M e d ika Loka W o n og iri

(M W o n o g iri) W o n o g iri

R u m a h S a kit /

H o s p ita l 2 02 0 2 02 0 9 9,0 0% 9 9,0 0% 45.601 4 0 .2 1 0 PT M e d ika Loka S a la tig a

P eka lo ng a n R u m a h S a kit /

(M S alatig a) H o s p ita l 2 02 0 2 02 0 9 9,0 0% 9 9,0 0% 4 0 .7 1 5 3 6 .9 2 4 J a s a M a n aje m e n

PT M e d ika Loka M an aje m e n

J a k a rta d an K o n su lta si / (M M a n aje m e n ) M a n a g e m e n t

S e rv ic e a n d C o n s u lta tio n

2 0 1 9 9 9,9 0% 9 9,9 0% 5 .1 2 0 3 .2 9 9

PT M e d ika Loka S o rea ng R u m a h S a kit /

(M S o re a n g ) B a n d u n g H o s p ita l 2021 9 9,9 0% 9 9,9 0% 3 4 .9 3 3 PT M e d ika Loka C iled ug R u m a h S a kit /

(M C iled ug ) T a n g e ra n g H o s p ita l 2021 9 9,9 0% 9 9,9 0% 5 4 .7 5 6 Tidak langsung melalui

masing-masing Mitra/Indirect through each Mitra

PT M e d ika lo ka P aste ur R u m a h S a kit /

(M Pasteur) B a n d u n g H o s p ita l 2 0 0 3 2 0 0 4 6 0,0 0% 6 0,0 0% 1 88 .11 6 152.051 PT M e d ika lo ka P an d an aran R u m a h S a kit /

(M P an d an aran ) S e m a ra n g H o s p ita l 2 0 0 4 2 0 0 4 5 7,1 4% 5 7,1 4% 1 15 .74 4 9 2 .5 4 6 PT M e d ika lo ka S u ka b u m i R u m a h S a kit / (M S uka b u m i) S u ka b u m i H o s p ita l 2 0 0 6 2 00 7 7 7,0 0% 7 7,0 0% 1 08 .10 3 1 0 1 .97 4 PT M e d ika lo ka T a n g e ra n g R u m a h S a kit / (M T a n g e ra n g ) T a n g e ra n g H o s p ita l 2 00 7 2 0 0 8 6 7,5 0% 6 7,5 0% 2 3 9 .4 3 9 2 0 5 .2 8 6 PT M e d ika lo ka G ra n d B e ka si R u m a h S a kit /

(M G ra n d B eka si) B eka si H o s p ita l 2 0 0 8 2 0 0 9 5 4,0 0% 5 4,0 0% 2 6 8 .9 9 6 2 3 5 .1 0 6 PT M e d ika lo ka A rc a m a n ik R u m a h S a kit /

(M A rca m a n ik) B a n d u n g H o s p ita l 2 0 0 8 2 01 0 7 0,0 0% 7 0,0 0% 2 0 2 .0 3 4 1 3 3 .07 5 PT M e d ika lo ka G a la x y R u m a h S a kit /

(M G alaxy) B eka si H o s p ita l 2 01 0 2 01 0 6 0,0 0% 6 0,0 0% 127.401 1 1 4 .40 7 PT M e d ika lo ka P alem b a ng R u m a h S a kit /

(M P alem b a ng ) P a lem b a ng H o s p ita l 2 01 0 2011 5 5,5 0% 5 5,5 0% 1 92 .00 7 1 8 0 .17 9 PT M e d ika lo ka C ip u ta t R u m a h S a kit /

(M C iputat) T a n g e ra n g H o s p ita l 2 01 0 2011 5 5,0 0% 5 5,0 0% 1 72 .38 6 1 4 0 .99 6 PT M e d ika lo ka C ileu ng si R u m a h S a kit /

(M C ileu ng si) B o g o r H o s p ita l 2011 2 0 1 3 6 5,0 0% 6 5,0 0% 1 48 .74 3 1 3 4 .64 0 PT M e d ika lo ka B a n y u m a n ik R u m a h S a kit / (M B a n yu m a n ik) S e m a ra n g H o s p ita l 2 0 1 3 2 0 1 3 6 5,0 0% 6 5,0 0% 1 15 .32 8 1 0 4 .51 0 PT M e d ika lo ka S e rp o n g R u m a h S a kit / (M S erpo ng ) T a n g e ra n g H o s p ita l R u m a h S a kit / 2 0 1 3 2 0 1 4 5 1,0 0% 5 1,0 0% 1 09 .84 5 9 0 .7 8 5 PT M e d ika lo ka S o lo (M S olo) S olo H o s p ita l 2 0 1 3 2 0 1 4 5 5,0 0% 5 5,0 0% 1 46 .01 0 1 2 4 .43 2

(17)

____________ kecuali Disebutkan Lain)_____________ 1. UMUM (lanjutan)

c. Entitas Anak (lanjutan)

Melalui kepemilikan langsung Perusahaan di MM Pasteur, MM Pandanaran, MM Sukabumi,

MM Tangerang, MM Grand Bekasi,

MM Arcamanik, MM Galaxy, MM Palembang, MM Ciputat, MM Cileungsi, MM Banyumanik, MM Solo dan MM Serpong, Perusahaan juga memperoleh kepemilikan tidak langsung di M Pasteur, M Pandanaran, M Sukabumi, M Tangerang, M Grand Bekasi, M Arcamanik, M Galaxy, M Palembang, M Ciputat, M Cileungsi, M Banyumanik, M Solo, M Serpong, M Ciledug dan M Soreang.

Pada tanggal 30 Juni 2021 dan 31 Desember 2020, seluruh Entitas Anak yang telah memulai

operasi komersial memiliki izin

penyelenggaraan rumah sakit yang berlaku selama 5 tahun sejak penerbitan izin.

Berdasarkan Akta Pernyataan Keputusan

Rapat Umum Pemegang Saham yang

diaktakan dengan akta Notaris Risbert, S.H., M.H. No. 32 tanggal 17 Maret 2020, para pemegang saham MMF telah mengambil keputusan untuk melikuidasi MMF. Sampai

dengan tanggal penyelesaian laporan

keuangan interim konsolidasian, proses

likuidasi MMF masih dalam proses.

Perubahan Persentase Kepemilikan Entitas Anak

Sampai dengan Juni 2021, M Karawang, M Manado, M Pekanbaru, M Lampung, M

Pekalongan melakukan peningkatan pada

jumlah lembar saham dan modal disetor, sehingga kepemilikan Perusahaan pada entitas masing-masing sebesar 73,25%%, 87,25%, 79,00%, 66,25%, 82,91%.

c. Subsidiaries (continued)

Through the Company’s direct ownership in MM Pasteur, MM Pandanaran, MM Sukabumi,

MM Tangerang, MM Grand Bekasi,

MM Arcamanik, MM Galaxy, MM Palembang, MM Ciputat, MM Cileungsi, MM Banyumanik, MM Solo and MM Serpong, the Company also obtained indirect ownership in M Pasteur, M Pandanaran, M Sukabumi, M Tangerang, M Grand Bekasi, M Arcamanik, M Galaxy,

M Palembang, M Ciputat, M Cileungsi,

M Banyumanik, M Solo, M Serpong, M Ciledug and M Soreang.

As of June 30, 2021 and December 31, 2020, all of the Subsidiaries that have started the commercial operations already have operating license of hospitals valid for 5 years upon the issuance of the license.

Based on the General Shareholders Meeting notarized by Notary Deed of Risbert, S.H., M.H. No. 32 dated March 17, 2020, the shareholders of MMF resolved to liquidate MMF. As of the completion date of the interim consolidated financial statements, MMF liquidation process is still in process.

Change in Ownership Percentage of

Subsidiaries

Up to June 2021, M Karawang, M Manado, M Pekanbaru, M Lampung, M Pekalongan increased its number of shares and paid-up capital, so that the Company’s ownership in the entity amounted to 73.25%%, 87.25%, 79.00%, 66.25%, 82.91%.

(18)

(Disajikan dalam Jutaan Rupiah, _____________ kecuali Disebutkan Lain)__________

1. UMUM (lanjutan)

Perubahan Persentase Kepemilikan Entitas Anak (lanjutan)

Sampai dengan Juni 2021, Perusahaan

meningkatkan kepemilikannya di beberapa entitas anak dengan persentase kenaikan

kepemilikan Perusahaan adalah sebagai

berikut: M Husada M Pasteur M Pandanaran M Grand wisata M Arcamanik M Cileungsih M Banyumanik M Ciruas M Bitung M Medan M Samarinda M Jakabaring M Kendari M Podomoro MM Pasteur MM Sukabumi MM Tangerang MM Arcamanik MM Palembang MM Ciputat MM Cileungsi

Selama tahun 2020, M Balikpapan, M Medan, M Padang, M Purwokerto, M Samarinda, M Jakabaring, M Kendari, M Manado, M Podomoro, M Pekanbaru, M Lampung, M Pekalongan, M Husada melakukan peningkatan pada jumlah lembar saham dan modal disetor, sehingga kepemilikan Perusahaan pada entitas masing- masing sebesar 61,50%, 66,00%, 67,50%, 62,85%, 81,50%, 58,00%, 80,40%, 99,91%, 85,38%, 79,55%, 66,50%, 82,32%, 78,75%.

Selama tahun 2020, Perusahaan

meningkatkan kepemilikannya di beberapa entitas anak dengan persentase kenaikan

kepemilikan Perusahaan adalah sebagai

berikut: M Husada M Grand Bekasi M Arcamanik M Ciputat M Makassar M Balikpapan M Medan M Jakabaring M Banyumanik MM Tangerang MM Ciputat MM Cileungsi MM Grand Bekasi c. Subsidiaries (continued)

Change in Ownership Percentage of Subsidiaries (continued)

As of June 2021, the Company increased its ownership in several subsidiaries with the details of increased percentage of ownership as follows: 1,00% 1,50% 0,36% 1,00% 1,00% 0,50% 0,50% 0,50% 0,83% 0,50% 1,00% 0,50% 0,10% 0,12% 0,83% 1,95% 0,74% 2,86% 0,90% 0,91% 1,54% M Husada M Pasteur M Pandanaran M Grand wisata M Arcamanik M Cileungsih M Banyumanik M Ciruas M Bitung M Medan M Samarinda M Jakabaring M Kendari M Podomoro MM Pasteur MM Sukabumi MM Tangerang MM Arcamanik MM Palembang MM Ciputat MM Cileungsi On 2020, M Balikpapan, M Medan, M Padang, M Purwokerto, M Jakabaring, M Kendari, M Manado, M Podomoro, M Pekanbaru, M Lampung, M Pekalongan, M Husada increased its number of shares and paid-up capital, so that the Company’s ownership in the entity

amounted to 61.50%, 66.00%, 67.50%,

62.85%, 81.50%, 58.00%, 80.40%, 99.91%, 85.38%, 79.55%, 66.50%, 82.32%, 78.75%.

On 2020, the Company increased its ownership in several subsidiaries with the details of increased percentage of ownership as follows: 1,00% M Husada 0,50% M Grand Bekasi 0,50% M Arcamanik 0,25% M Ciputat 2,50% M Makassar 2,06% M Balikpapan 0,29% M Medan 0,25% M Jakabaring 0,50% M Banyumanik 0,74% MM Tangerang 0,91% MM Ciputat 2,31% MM Cileungsi 0,09% MM Grand Bekasi

(19)

_____________ kecuali Disebutkan Lain)_____________ 1. UMUM (lanjutan)

Perubahan Persentase Kepemilikan Entitas Anak (lanjutan)

Selisih antara penyesuaian kepentingan

nonpengendali dengan nilai wajar imbalan yang diberikan diakui sebagai bagian dari "Selisih Transaksi dengan Pihak Nonpengendali" dalam laporan posisi keuangan interim konsolidasian pada tanggal 30 Juni 2021 dan 31 Desember 2020.

Harga akuisisi dan nilai buku dari aset neto adalah sebagai berikut:

30 Juni 2021/

June 30, 2021

Nilai buku dari aset neto yang dialihkan oleh

kepentingan nonpengendali 250.208 Nilai wajar imbalan yang diberikan

(harga akuisisi) (764.191)

Selisih nilai transaksi dengan

pihak nonpengendali (513.983)

c. Subsidiaries (continued)

Change in Ownership Percentage of Subsidiaries (continued)

The difference between non-controlling interest adjustments and the fair value of the consideration paid was recognized as part of “Difference in Value of Transactions with Non

Controlling Interest” in the interim

consolidated statement of financial position as of June 30, 2021 and December 31, 2020. Acquisition price and the related book value of the net assets are as follows:

31 Desember 2020/

December 31, 2020

Book value of net assets transferred

262.123 by non-controlling interests Fair value of consideration paid

(775.525) (acquisition price) Difference in value of transactions

(513.402) with non-controlling interests

Pendirian Entitas Anak baru

Sampai dengan Juni 2021, Perusahaan telah mendirikan M Ciledug dan M Soreang sebagai entitas anak.

Selama tahun 2020, Perusahaan telah

mendirikan M Wonogiri dan M Salatiga sebagai entitas anak.

Establishment of new Subsidiaries

As of June 2021, the Company has established M Ciledug and M Soreang as subsidiaries.

On 2020, the Company has established M Wonogiri and M Salatiga as subsidiaries.

(20)

d. Dewan Komisaris, Direksi, Komite Audit, Sekretaris Perusahaan, Kepala Unit Audit Internal dan Karyawan

Susunan Dewan Komisaris dan Direksi

Perusahaan pada tanggal 30 Juni 2021 dan 31 Desember 2020 adalah sebagai berikut:

d. The Boards of Commissioners and

Directors, Audit Committee, Corporate Secretary, Head of Internal Audit Unit and Employees

The composition of the Company’s Boards of Commissioners and Directors as of June 30, 2021 and December 31, 2020 was as follows:

Dewan Komisaris

Komisaris Utama Wakil Komisaris Utama

Komisaris Komisaris Komisaris Independen Komisaris Independen Komisaris Independen Direksi Direktur Utama Direktur Direktur Direktur Independen

Paulus Kusuma Gunawan Husen Sutakaria

Sudarsono Darwin Cyril Noerhadi

Alexander Rusli Heridadi Amit Varma

Hasmoro Yulisar Khiat

Binsar Parasian Simorangkir Aristo Setiawidjaja

Board of Commissioners President Commissioner Vice President Commissioners Commissioner Commissioner Independent Commissioner Independent Commissioner Independent Commissioner Board of Directors President Director Director Director Independent Director

Susunan Komite Audit Perusahaan pada tanggal 30 Juni 2021 dan 31 Desember 2020 adalah sebagai berikut:

The composition of the Company’s Audit Committee as of June 30, 2021 and December 31, 2020 was as follows: Komite Audit Ketua Anggota Anggota Audit Committee

Alexander Rusli : Chairman

Haryanto Sahari : Member

Myrnie Zachraini T. : Member

Sekretaris Perusahaan pada tanggal 30 Juni 2021 dan 31 Desember 2020 adalah Susi Setiawaty.

Ketua Unit Audit Internal Perusahaan pada tanggal 30 Juni 2021 dan 31 Desember 2020 adalah Sri Haryanti Marsiyo.

Personel manajemen kunci Perusahaan

meliputi seluruh anggota Dewan Komisaris dan Direksi. Manajemen kunci tersebut memiliki

kewenangan dan tanggung jawab untuk

merencanakan, memimpin, dan mengendalikan aktivitas Perusahaan.

Pada tanggal 30 Juni 2021 dan 31 Desember 2020, Grup memiliki masing-masing 10.547 dan 9.682 karyawan tetap.

The Company’s Corporate Secretary as of June 30, 2021 and December 31, 2020 was Susi Setiawaty.

Head of the Company’s Internal Audit Unit as of June 30, 2021 and December 31, 2020 was Sri Haryanti Marsiyo.

The boards of Commissioners and Directors

are the Company’s key management

personnel. The key management has the authority and responsibility for planning, directing and controlling the activities of the Company.

As of June 30, 2021 and December 31, 2020, the Group has a total of 10,547 and 9,682 permanent employees, respectively.

(21)

e. Penyelesaian dan persetujuan Laporan Keuangan Interim Konsolidasian

Manajemen Perusahaan bertanggung jawab atas penyusunan dan penyajian wajar laporan keuangan interim konsolidasian ini, yang telah diselesaikan dan disetujui untuk diterbitkan

oleh Direksi Perusahaan pada tanggal

31 Juli 2021.

2. IKHTISAR KEBIJAKAN AKUNTANSI PENTING

a. Kepatuhan Terhadap Standar Akuntansi Keuangan (“SAK”)

Laporan keuangan interim konsolidasian Grup telah disusun dan disajikan sesuai dengan SAK di Indonesia yang meliputi Pernyataan Standar Akuntansi Keuangan (“PSAK”) dan Interpretasi Standar Akuntansi Keuangan (“ISAK”) yang diterbitkan oleh Dewan Standar Akuntansi Keuangan Ikatan Akuntan Indonesia (“DSAK - IAI”), dan peraturan terkait yang diterbitkan oleh Otoritas Jasa Keuangan (“OJK”), khususnya Peraturan No. VIII.G.7, Lampiran Keputusan Ketua OJK No. Kep-347/BL/2012 tanggal 25

Juni 2012 tentang “Penyajian dan

Pengungkapan Laporan Keuangan Emiten atau

Perusahaan Publik”. Kebijakan ini telah

diterapkan secara konsisten terhadap seluruh tahun yang disajikan, kecuali jika dinyatakan lain.

b. Dasar Penyusunan Laporan Keuangan konsolidasian

Laporan keuangan interim konsolidasian telah disusun sesuai dengan Pernyataan Standar Akuntansi Keuangan PSAK 1, “Penyajian Laporan Keuangan”.

Laporan keuangan interim konsolidasian,

kecuali laporan arus kas interim konsolidasian, telah disusun berdasarkan konsep akrual dan menggunakan konsep biaya historis kecuali diungkapkan lain dalam catatan terkait di sini.

Laporan arus kas interim konsolidasian, yang

disusun dengan menggunakan metode

langsung, menyajikan penerimaan dan

pengeluaran kas dan bank yang diklasifikasikan ke dalam aktivitas operasi, investasi dan

e. Completion and approval of Interim Consolidated Financial Statements

The Company’s management is responsible for the preparation and fair presentation of

these interim consolidated financial

statements, which were completed and authorized for issuance by the Board of Directors of the Company on July 31, 2021.

2. SUMMARY OF SIGNIFICANT ACCOUNTING

POLICIES

a. Compliance with Financial Accounting Standards (“SAK")

The Group’s interim consolidated financial

statements have been prepared and

presented in accordance with Indonesian SAK which comprise, the Statements of Financial

Accounting Standards (“PSAK”) and

Interpretation of Financial Accounting

Standards (“ISAK”) issued by Financial Accounting Standards Board of the Indonesian Institute of Accountants (“DSAK-IAI”) and the related Financial Services Authority’s (“OJK”) regulation particularly Rule No. VIII.G.7, Appendix of the Decision Decree of the Chairman of OJK’s decision No. Kep- 347/BL/2012 dated June 25, 2012 on

“Financial Statements Presentation and

Disclosures for Issuers and Public

Companies”. These policies have been

consistently applied to all years presented, unless otherwise stated.

b. Basis of Preparation of the Consolidated Financial Statements

The interim consolidated financial statements have been prepared in accordance with

PSAK 1, “Presentation of Financial

Statements”.

The interim consolidated financial statements, except interim consolidated statement of cash flows, have been prepared on the accrual basis using the historical cost concept of accounting, except as otherwise disclosed in the related notes herein.

The interim consolidated statement of cash flows, which has been prepared using the

direct method, presents receipts and

disbursements of cash on hand and in banks classified into operating, investing and